Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 入组人数
- 240
- 试验地点
- 21
- 主要终点
- Acute treatment with elimination of AF episodes
研究概览
简要总结
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.
详细描述
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting an estimated 2.2 million persons in the United States (US). In addition to being debilitating, AF has been identified as a leading risk factor for stroke. AF is often associated with structural heart disease, but a substantial number of AF patients have little or no detectable structural heart disease. A patient with AF is up to 5 times more likely to have a stroke than the general population.
Recently, it has been demonstrated that for a significant portion of AF patients (80% - 95 %) the arrhythmia originates in one of the four pulmonary veins (PV's). Furthermore, it has been shown that isolation of this arrhythmia by ablation can, in the majority of patients (50-70%), eliminate or markedly reduce episodes of AF. Currently, there are a number of modalities being investigated to treat AF. They include radiofrequency, laser, thermal, cryo, microwave, and ultrasound ablation of targeted areas in the atrium and/or PVs.
Comparison(s): Clinical success of High Intensity Focused Ultrasound (HIFU) Ablation for Pulmonary Vein Isolation in the treatment of Atrial Fibrillation, compared to medical therapy with anti-arrhythmic drugs (AADs).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented atrial fibrillation
- •Failed or intolerant to at least 1 anti-arrhythmic drug
- •Able to take anti-coagulant therapy
- •Able to complete screening tests required for inclusion/exclusion criteria
- •Able to take at least 1 approved anti-arrhythmic drug
- •Not pregnant
- •Available for follow-up for at least 12 months
排除标准
- •Persistent or permanent atrial fibrillation
- •Mitral disease
- •Prior surgical treatment for atrial fibrillation
- •Ablation for treatment of atrial fibrillation within 6 months
- •Severe left ventricular hypertrophy
- •Known untreated coagulopathy
- •Unstable angina
- •Prior stroke
- •Uncontrolled heart failure
- •Secondary causes of atrial fibrillation
- •Uncorrected hyperthyroidism within 12 months
- •Pulmonary embolism within 6 months
- •Pneumonia or acute pulmonary disease within 3 months
- •Pacemaker/ICD
- •High risk for esophageal disease
- •Currently enrolled in investigational drug or device study
研究组 & 干预措施
Control
Class I or III anti-arrhythmic drug for the treatment of AF
干预措施: propafenone (Drug)
Control
Class I or III anti-arrhythmic drug for the treatment of AF
干预措施: flecainide (Drug)
Control
Class I or III anti-arrhythmic drug for the treatment of AF
干预措施: dofetilide (Drug)
Control
Class I or III anti-arrhythmic drug for the treatment of AF
干预措施: sotolol (Drug)
Control
Class I or III anti-arrhythmic drug for the treatment of AF
干预措施: Amiodarone (Drug)
Treatment
Pulmonary vein ablation with HIFU
干预措施: Pulmonary vein ablation (Device)
结局指标
主要结局
Acute treatment with elimination of AF episodes
时间窗: 12 months
Death, stroke, and hospitalization for recurrence of AF
时间窗: within 12 months of treatment
次要结局
- Acute treatment success(60 days)